: A Phase 1 Trial Using CellReady® in Alzheimer’s Disease

CHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s Disease

CHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s DiseaseToulouse, May 23rd 2025 Cell-Easy, a Contract Development and Manufacturing Organization (CDMO) specialized in advanced cell therapies, announces that its allogeneic adipose-derived mesenchymal stem cell product, CellReady®, will be investigated in a newly

Cell-Easy Expands its GMP Cell Therapy Manufacturing Facility

Cell-Easy Expands its GMP Cell Therapy Manufacturing Facility to Support Growing Client Demand. New state-of-the-art class-B cleanrooms, development labs, and logistics upgrades accelerate scalable production of autologous & allogeneic cell therapies in compliance with FDA/EMA standards. Toulouse, France –April 9th – Cell-Easy, a leading European Contract Development and Manufacturing Organization (CDMO) specializing

CTA Approval to initiate ALLOFIST

CHU Toulouse receives CTA Approval to initiate ALLOFIST, a Phase 1/2 Trial based on Cell-Easy’s proprietary adipose-derived MSC in Patients suffering from Crohn Disease. Toulouse, France, January 15, 2025   The long-term partnership between Cell-Easy and Toulouse University Hospital (CHU Toulouse) continues to bear fruits, bringing innovative MSC-based therapies to

Accelerating Patient Access to Advanced Cell-based Therapies through the Signature of a Service Agreement between the French CDMO and the Toulouse University Hospital (CHU Toulouse).

Accelerating Patient Access to Advanced Cell-based Therapies through the Signature of a Service Agreement between the French CDMO and the Toulouse University Hospital (CHU Toulouse) Toulouse, France, April 18, 2024 – This agreement between the two parties opens great perspectives for Biotechs, providing them with seamless access to patients who

CAR (chimeric antigen receptor) T-cell illustration.

Cell-Easy Signs Groundbreaking Manufacturing Contract, Paving the Way for Local Hospitals to Offer Next-Generation CAR-T Therapy.

The accumulated expertise among various programs as well as our local partnerships have been the foundation to close such a deal. I’m a true believer that our positioning can be beneficial for other biotech seeking to easily access patient cohorts. Alexis Delbaere Tweet About Cell-Easy Cell-Easy is a science-centric CDMO

Cell-Easy and Toulouse University Hospital obtain IMPD approval for first-in-human clinical trial in systemic sclerosis, using promising allogeneic approach

EU regulatory approval to administer Adipose-derived mesenchymal Stem Cells (ASCs) in patients with ischemic digital ulcers marks key milestone for partners Toulouse, France, November 16, 2023 – Cell-Easy, a French Contract Development and Manufacturing Organization (CDMO) focused on advanced cell therapies, and the Toulouse University Hospital, today announce that they